BioSpace News Archive

National Association of Chronic Disease Directors CEO John W. Robitscher , MPH, participated in the 4th biannual Greater Horn Oncology Symposium (GHOS) held Sept. 23-25.

On behalf of the more than 6 million Americans living with Alzheimer’s disease and their families, the Alzheimer’s Association enthusiastically welcomes the positive topline data reported by Eisai and Biogen on the CLARITY AD global Phase 3 clinical trial of lecanemab.

BioArctic AB’s partner Eisai announced positive topline results for the large global Phase 3 confirmatory Clarity AD study in 1,795 subjects.

NeuroSigma, Inc. announced that the Centers for Medicare & Medicaid Services has confirmed the durable medical equipment benefit category determination and two permanent Level II Healthcare Common Procedure Coding System codes for the Monarch eTNS® System, effective October 1, 2022, as part of the final coding decisions of its biannual update.

AustinPx, Pharmaceutics and Manufacturing, a contract development and manufacturing organization, announced the appointment of Elizabeth Hickman as Chief Business Officer.

Todos Medical, Ltd. today announced that its majority-owned joint venture 3CL Pharma Ltd. received a Notice of Allowance issued by the USPTO for the Company’s proprietary SARS-CoV-2.

Ambulero, Inc. announces it received a positive response from a Type B Pre-IND meeting with the FDA to develop AMB-301 as a treatment for a rare vascular condition called Buerger’s Disease.

The global Protein Expression market size is expected to hit around US$ 13.0 billion by 2030, according to a new report by Vision Research Reports.

The global PEGylated proteins market was surpassed at USD 12,786 million in 2021 and is expected to hit around USD 22,967 million by 2030, growing at a CAGR of 7.2% from 2022 to 2030.

The latest market analysis report published by Reports and Data, titled ‘Global Blastomycosis Treatment Market – Forecast to 2030,’ thoroughly examines the Blastomycosis Treatment industry to provide essential data & information for the targeted readers